INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors

Completed

• Conditions: Pancreas Cancer; Pancreatic Adenocarcinoma

• Registration Number: NCT04436679
• Lead Sponsor: University Hospital, Lille

Brief Summary

The study is particularly innovative as it will accurately analyze the microscopic characteristics of the stroma, tumor budding and mucin expression in adenocarcinomas of the pancreas, using a comparative approach of long-survivor/short-survival patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-06-15
• Study First Submitted QC: 2020-06-15
• Study First Posted: 2020-06-18
• Study Start: 2021-02-02
• Primary Completion: 2025-02-22
• Study Completion: 2025-02-22
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-25
• Last Update Posted: 2025-03-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 342

Inclusion Criteria

• Patients > 18 years of age at diagnosis
• Primary pancreatic cancer patients operated on in one of the 4 centres between 2001 and 2016
• Histopathological diagnosis of excreto-pancreatic adenocarcinoma of the pancreas, ductal adenocarcinoma or classical adenocarcinoma
• Tissue blocks (FFPE) available (tumour/healthy tissue)
• Affiliated to a social security scheme

Exclusion Criteria

• Absence of Primary Cancer Tissue Blocks (PCTBs)
• Paraffin block fixed in Bouin or AFA
• Patient Refusal
• Pancreatic cancer not corresponding to a conventional excretopancreatic adenocarcinoma such as: carcinoma on intraductal papillary mucinous neoplasm, endocrine tumor/carcinoma, acinar cell carcinoma, ...).
• Patient died due to post-surgical complications (death within 30 days post-surgery).
• Surgical resection of macroscopic R2 type.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relationship between known prognostic histological markers of pancreatic adenocarcinoma and patient survival.	at 2 years	Tissue analysis will be performed by conventional microscopy and will evaluate histological markers known in the literature to have a prognostic impact.

Secondary Outcome Measures

Name	Time	Method
Relationship between newly described histological markers for pancreatic adenocarcinoma and patient survival.	at 2 years	Immunohistochemistry tissue analysis. It will allow the evaluation of newly described histological markers for pancreatic adenocarcinoma, which could have a prognostic impact such as the immunophenotype of the inflammatory infiltrate, the expression of the mucins MUC1, MUC5AC, MUC4, MUC16, mesothelin, p53, Ki67 (MIB1) and markers of aggressive subtypes identified by transcriptome studies, in particular the basal-like molecular subtype.

Trial Locations

Locations (1)

Hop Claude Huriez Chu Lille; 🇫🇷 Lille, France